Despite the recent advances in the management of
cervical cancer using
cisplatin-based
concurrent chemoradiotherapy, substantial treatment failure still occurs, especially in advanced-stage patients and early-stage
cervical cancer patients with high-risk prognostic factors. Therefore, efforts to further improve the survival and quality of life of these patients are necessary.
Nedaplatin (cis-diammine-glycoplatinum), a derivative of
cisplatin, was developed with the aim of producing a treatment with a similar effectiveness to
cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies, the clinical efficacy of
nedaplatin as a
radiosensitizing agent was evaluated in patients with
cervical cancer. Retrospective analysis of
nedaplatin-based
concurrent chemoradiotherapy (CCRT) against
cervical cancer suggested that
nedaplatin-based CCRT can be considered as an alternative to
cisplatin-based CCRT in both early-stage and advanced-stage
cervical cancer patients. However, due to the lack of a randomized controlled study,
nedaplatin-based CCRT has not been convincingly proven to be clinically effective in patients with
cervical cancer. Further investigations in randomized controlled trials are therefore needed.